POCT facilitates the shift called for by the NHS Long Term Plan by enabling patients to receive care through a more adaptive, community-based approach. 4 Abbott has a range of POCT devices and a ...

Abbott Laboratories, Agilent Technologies Inc ... with a focus on oncology and POC testing. Companies like Grifols, Qiagen, and FDA-approved products are leading the market.

Driven by Rising Geriatric Population and disease Prevalence, The Molecular Diagnostics market Grows Steadily, Focusing On DNA and Bimolecular Innovations.

report_id=AMR1008 Technological advancements, such as next-generation sequencing (NGS), molecular diagnostics, and point-of-care testing (POCT), are revolutionizing ... in the in vitro diagnostics ...

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen ...

The global in vitro diagnostics (IVD) market has exhibited significant growth, with its valuation rising from $67,111 million in 2019 to an estimated $91,093 million by 2027. This ...

Fourth-generation assays: The fourth-generation EIAs, including the Abbott Architect HIV Ag/Ab Combo ... minutes and can be used in point-of-care (POC) settings. Since this test presents both ...

The POC hs-cTnI assay was performed using the Siemens Healthineers ... 14 15 The laboratory hs-cTnI assay was performed using the Abbott ARCHITECT STAT High Sensitive Troponin-I kit run on the Abbott ...